Although C5b-9 levels were not evaluated in pegcetacoplan clinical trials, this was demonstrated in a clinical trial conducted in patients with another complement regulatory disorder, C3G, in which serum C3 concentrations increased and plasma-soluble C5b-9 (sC5b-9) concentrations decreased after 48 weeks of pegcetacoplan treatment [32]. This evidence concerns the gene C3 and complement 3 glomerulopathy.